Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

PARETO ADVISES JOTUL HOLDINGS ON THE SUCCESSFUL PLACEMENT OF A NOK 250 MILLION FULLY UNDERWRITTEN SENIOR SECURED BOND

Pareto Securities has advised Jotul Holdings S.à r.l., a special purpose vehicle established by funds controlled by OpenGate Capital Management, LLC, on placing a 4-year NOK 250 million senior secured bond (the “Bonds”). The proceeds from the transaction will be used to help finance the acquisition of Jøtul A/S, a leading manufacturer of residential stoves and fireplaces, from Ratos AB. The Bonds, maturing in January 2022, will bear a floating rate coupon of 3 month NIBOR + 7.00 per cent, with interest paid quarterly. The Bonds will be listed on a regulated market within 12 months of the

Boost.ai secures 5 million dollar investment to expand internationally

Boost.ai, one of the fastest growing AI companies in the Nordics, receives Series A funding for international expansion from leading VC firm, Alliance Venture.Stavanger – 14. February 2018: Boost.ai, provider of some of the world’s most robust chatbots and virtual assistants, today announced the closing of a new round of financing from Alliance Venture. The terms of the transaction were not disclosed, but the deal will potentially inject up to 5 million dollars into the company. The company ownership will remain firmly in the hands of the founders and employees, who still retain more than

Science Translational Medicine publishes research results from Oblique Therapeutics and Karolinska Institute on a new treatment of advanced cancer

The Gothenburg, Sweden based biotech company Oblique Therapeutics AB today announced that the world-leading medical journal Science Translational Medicine in its latest issue has published promising preclinical research results on a new type of molecules against advanced cancer. The results are based on a collaboration with Professor Elias Arnér's research group at Karolinska Institute in Stockholm. In the article, titled Irreversible Inhibition of Cytosolic Thioredoxin Reductase 1 as a Mechanistic Basis for Anticancer Therapy, the researchers show that tumor growth is effectively

Injection Molded Structural Electronics (IMSE™) Leader TactoTek™ Secures $23 Million Funding to Accelerate Growth

Second close of series B funding round attracts financial and strategic investors committed to accelerating IMSE solution development and market penetrationOULU, FINLAND (15 February 2018) – Today TactoTek™, the leading developer of injection molded structural electronics (IMSE™) solutions, announced that it has closed $23 million in funding. The investment round attracted new strategic investors, Ascend Capital Partners, Nanogate, and Plastic Omnium, continuing participation from prior investors, including Conor Venture Partners and Faurecia Ventures, as well as debt instruments and grants.

SimCorp Dimension Selected by German Pension Fund, SOKA-BAU, As Its New Front to Back Investment Management Platform

SimCorp Press Release SimCorp , a leading provider of investment management solutions  and services to the global financial services industry, today announced that SOKA-BAU, a German pension fund serving the construction industry, has selected SimCorp Dimension as its new front to back office investment management platform. The agreement, signed in December 2017, will serve to innovate and consolidate SOKA-BAU’s current systems and architecture, to provide the fund with an operationally efficient and integrated investment management setup.

INTERIM REPORT, FOURTH QUARTER OF 2017

October– December 2017 The numbers refer to the remaining operations · Q4 marked the final period of major restructuring, “cleaning up”, and legacy issue resolution, initiated in July 2017. · Net sales for the period SEK 29 million (34) · Operating result for the period after nonrecurring items attributable to restructuring SEK -15 million · Operating loss for the period SEK -13,7 million (-4,1) · Loss after tax for the period SEK -27 million (-6) · Earnings per share SEK -0,46 (-0.10) · Cash flow before changes in working capital for the period SEK -46,1 million (-

Pihlajalinna Plc: Managers’ transactions

Pihlajalinna Plc     Managers’ transactions     15 February 2018 at 9:40 Pihlajalinna Plc: Managers’ transactions Pihlajalinna Plc has received the following notification on 15 February 2018: Person subject to the notification requirementName: MWW yhtiö Oy Legal PersonPosition: Closely associated person Person discharging managerial responsibilities in issuerName: Wiren Mikko WaldemarPosition: Member of the Board/Deputy member

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 2 pm on Thursday 22 March 2018 at Medicon Village, Scheelevägen 2, in Lund, Sweden.Entitlement to participate and notification Shareholders that wish to participate at the Extraordinary General Meeting should: · be included in the share register maintained by Euroclear Sweden AB on Friday 16 March 2018, and · notify the company by email to anmalan@neurovive.com or, in writing to NeuroVive Pharmaceutical AB, Medicon Village, Scheelevägen 2, 223 81

Metsä Tissue invests in new Away-from-Home production line in Raubach mill

Metsä Tissue is investing in a new production line for hand towels in its Raubach mill in Germany. The total investment is approximately EUR 10 million and the new production line for Away-from-Home products will be operative by the end of 2018. “The demand for tissue papers is expected to continue steady in all market areas. With this investment we want to strengthen our capacity and market position especially in the West European Away-from-Home markets. Raubach mill is conveniently located for serving the Continental customers, and with this investment, we can ensure prompt deliveries

Receipt of payment for KRI oil exports

15 February 2018 Genel Energy plc Receipt of payment for KRI oil exports Genel Energy plc (‘Genel’) announces that the Taq Taq partners have received a gross payment of $11.05 million from the Kurdistan Regional Government (‘KRG’) for oil sales during November 2017. Genel’s net share of the payment is $6.08 million. Genel also notes the announcement from DNO ASA, as operator of the Tawke PSC, that the Tawke partners have received $54.73 million from the KRG as payment for November 2017 crude oil deliveries to the export market from the Tawke licence. Genel's net share of the

Skandia and GHP expand collaboration for better care

Skandia and GHP already have collaboration regarding insurance customers in Stockholm with orthopaedic and spine injuries where the focus is on securing and maintaining the care chain for customers. This collaboration is now being expanded to also include customers in Gothenburg with these injuries.Health care in Sweden is far too fragmented and there is too little focus on the actual results of the care given. Closer cooperation with coherent and well-considered care chains can achieve higher quality and better use of the health care service’s resources. Skandia and GHP already have this

Year-end report 1 January - 31 December 2017

FOURTH QUARTER (OCTOBER-DECEMBER 2017) ·  Other operating income amounted to KSEK 0 (0) ·  Operating loss totalled KSEK -7,289 (-4,255) ·  Loss for the period totalled KSEK -7,315 (-4,255) ·  Cash flow from operating activities was KSEK -8,250 (-3,035) ·  Loss per share before dilution was SEK 0.35 (-0.36). Loss per share after dilution was SEK 0.19 (-0.36) ·  The proposed dividend is SEK 0.00/share (0.00) ·  This fourth quarter/year-end report has been prepared in accordance with RFR 2, Accounting for Legal Entities. The report has been prepared in accordance with

Båstad-Gruppen is growing – ChromoGenics’ dynamic glass ConverLight® selected when the facility in Ängelholm is further expanded.

ChromoGenics AB (publ) has received an order to deliver approximately 20m2 ConverLight® dynamic glass to Båstad-Gruppen in Ängelholm, Sweden, for the expansion of their offices. Peab Byggservice AB is the appointed building contractor for the project.Båstad-Gruppen, one of the leading suppliers of protective and professional shoes and boots in the Nordics with sales across Europe, will end up with a total of approximately 6,000 m2 of warehouse and office space after completing the expansion of its plant in Ängelholm. "We are currently going through an incredible expansion phase and will

NeuroVive decides on a Rights issue for continued drug development

Lund, Sweden, 15 February 2018, NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") on 15 February 2018 resolved, subject to approval by the Extraordinary General Meeting, to issue shares and warrants with preferential rights for existing shareholders ("Rights issue"). Upon full subscription to the Rights issue, the Company will receive approximately MSEK 78.5 before issuance costs. In full exercise of the warrants issued in the Rights issue, the Company will receive

Year-end report 2017

NET ASSET VALUE AND THE LATOUR SHARE ·The net asset value rose to SEK 95 per share, compared with SEK 87 per share at the beginning of the year. This is an increase of 11.6 per cent, adjusted for dividends. By comparison, the Stockholm Stock Exchange's Total Return Index (SIXRX) increased by 9.5 per cent. The net asset value was SEK 93 per share at 14 February. (1) ·The total return on the Latour share was 20.3 per cent during the year compared with 9.5 per cent for the SIXRX. ·The Board of Directors proposes that the dividend be increased to SEK 2.25 (2.00) per share.

Andreas Ivarsson — new Director of Projects & Developments at Wihlborgs

Wihlborgs’ Director of Projects & Developments Ulrika Hallengren is to take over the role as CEO of Wihlborgs when Anders Jarl is proposed as Chairman. In conjunction with this, Andreas Ivarsson will become the new Director of Projects & Developments.Andreas Ivarsson has been working as a property developer at Wihlborgs since August 2017. He joined Wihlborgs from a position as Area Manager for Skandia Fastigheter. Andreas worked at Skandia for eleven years where his duties included driving the Masthusen development in the Västra hamnen district of Malmö — an extensive urban regeneration

Promore Pharma Regains Rights for PXL01 Manufacturing

STOCKHOLM, SWEDEN, February 15, 2018 –  Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that it will assume responsibility for the manufacturing of the investigational medicinal product for the clinical Phase III trial for PXL01 and at the same time, the company regains the global manufacturing rights for the commercial product.In March 2016, Promore Pharma entered into an agreement with PharmaResearch Products Ltd ("PRP") regarding development collaboration on PXL01, complemented by a manufacturing agreement in January 2017. In accordance

Dow BioMedica to distribute Biohit GastroPanel® in Korea

Biohit Oyj Press release, 15[th] February, 2018 at 9.30 a.m. local time (EET) Biohit Oyj and Dow BioMedica have signed an agreement for the distribution of Biohit GastroPanel in Korea. The contract has been signed for four years with a continuation option. The registration will start during the 1[st] quarter of 2018. CEO Young Gill Shin, Dow BioMedica Inc.: “Korea has high incidence of Helicobacter pylori infection caused atrophic gastritis and related risks such as gastric cancer. GastroPanel as a primary examination will find patients for further examination, and allows more cost-

Selumetinib in NF1 gets FDA orphan drug status

15 February 2018 07:00 GMT SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION BY THE US FDA FOR NEUROFIBROMATOSIS TYPE 1 AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). NF1 is an incurable genetic condition that affects one in 3,000 births,[i]  with highly-variable symptoms, including cutaneous (skin), neurological (nervous system) and

Aspire Global Year-end report 2017

A strong fourth quarter led to record numbers in both revenue and EBITDA for the full year 2017Fourth quarter (Oct-Dec 2017) · Revenues increased by 27% to MEUR 19.2 (15.1) · B2B Revenues increased by 40% to MEUR 10.3 (7.3) · EBITDA increased by 35% to MEUR 3.8 (2.8) · EBITDA margin increased to 20% (19%) · EBIT increased by 33% to MEUR 3.5 (2.6) · Earnings after tax amounted to MEUR 3.3 (3.7) · Basic earnings per share*, after tax, from continued   operations amounted to EUR 0.03 (0.09) · First Time Depositors (FTDs) increased by 55% to 68.0 thousand (43.8)

REG Power Management Selects Greenbyte for Data Management

REG Power Management has selected Greenbyte’s modern software systems Breeze for wind farm management and Bright for solar PV plant management.REG Power Management, headquartered in Guildford UK, is a developer, owner and operator of renewable energy projects, with a track record of over 1000 MW. Greenbyte will work with REG Power Management to bring into Breeze and Bright their current portfolio of 30 wind farms and 10 solar PV plants. The systems will be used for real time production monitoring, streamlined reporting and in-depth data analysis over any time period to optimize plant energy

Bank of Lithuania issues inspection findings on Swedbank

During autumn 2017, the Bank of Lithuania has carried out an inspection related to Swedbank’s activities in the area of money laundering and terrorism financing prevention (AML/CTF) for the period January 2016 until March 2017.The findings include deficiencies in internal control systems for money laundering prevention, processes and documentation. Based on the results, Bank of Lithuania issued a warning to Swedbank and obliged to remedy identified deficiencies. -Swedbank takes the findings by Bank of Lithuania very seriously. We would like to emphasize that AML and CTF is a prioritised

There are no items matching the current filter
There are no more items matching the current filter
Back to top